| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/04/2004 | CA2496686A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 03/04/2004 | CA2496572A1 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| 03/04/2004 | CA2496272A1 Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer |
| 03/04/2004 | CA2496242A1 T-cell epitopes in staphylococcal enterotoxin b |
| 03/04/2004 | CA2496236A1 Preventives/remedies for cancer |
| 03/04/2004 | CA2495972A1 Heterocarpin, a plant-derived protein with anti-cancer properties |
| 03/04/2004 | CA2495962A1 Combination therapy for hyperproliferative diseases |
| 03/04/2004 | CA2495849A1 Ptk7 protein involvement in carcinoma |
| 03/04/2004 | CA2494974A1 Il-7 drug substance, composition, preparation and uses |
| 03/04/2004 | CA2494127A1 Pyrimido compounds having antiproliferative activity |
| 03/03/2004 | EP1394253A1 Anti-human ovarian cancer -anti-cd3 bispecific antibody |
| 03/03/2004 | EP1394152A1 2-iminoimidazole derivatives (1) |
| 03/03/2004 | EP1394147A1 Carboxylic acid derivative and medicine comprising salt or ester of the same |
| 03/03/2004 | EP1393776A1 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 03/03/2004 | EP1393750A2 Conjugates for treating an immune disease |
| 03/03/2004 | EP1393742A1 Use of protein kinase N beta |
| 03/03/2004 | EP1393731A1 Novel use of arylethenesulfonamide derivative |
| 03/03/2004 | EP1393730A2 Combination chemotherapy involving topotecan and a platinum coordination compound |
| 03/03/2004 | EP1393729A2 Combination chemotherapy involving topotecan and a platinum coordination compound |
| 03/03/2004 | EP1393719A1 Camptothecin-carboxylate formulations |
| 03/03/2004 | EP1393075A2 Methods of screening and using inhibitors of angiogenesis |
| 03/03/2004 | EP1392867A2 Antisense modulation of ptp1b expression |
| 03/03/2004 | EP1392852A2 Nucleic acid-associated proteins |
| 03/03/2004 | EP1392845A2 A g-protein coupled receptor and uses therefor |
| 03/03/2004 | EP1392830A2 Interleukin-18 mutants, their production and use |
| 03/03/2004 | EP1392829A2 Compositions and methods relating to lung specific genes and proteins |
| 03/03/2004 | EP1392823A2 Desaturase genes and uses thereof |
| 03/03/2004 | EP1392818A1 Chimeric immunoreceptor useful in treating human cancers |
| 03/03/2004 | EP1392733A2 Mammalian tumor susceptibility gene products and their uses |
| 03/03/2004 | EP1392730A2 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent |
| 03/03/2004 | EP1392702A1 Compounds and methods for inhibiting mrp1 |
| 03/03/2004 | EP1392701A1 Compounds and pharmaceutical compositions for inhibiting mrp1 |
| 03/03/2004 | EP1392694A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 03/03/2004 | EP1392688A1 Pyrazino[1',2':1,6]pyrido[3,4-b]indole1,4-dione derivatives |
| 03/03/2004 | EP1392685A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same |
| 03/03/2004 | EP1392683A1 SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF |
| 03/03/2004 | EP1392680A2 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| 03/03/2004 | EP1392669A1 Chromatographic separation method of paclitaxel and cephalomannin |
| 03/03/2004 | EP1392666A1 Biologically active methylene blue derivatives |
| 03/03/2004 | EP1392664A1 Epothilone derivatives |
| 03/03/2004 | EP1392662A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 03/03/2004 | EP1392654A1 Integrin antagonists |
| 03/03/2004 | EP1392651A1 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 03/03/2004 | EP1392648A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
| 03/03/2004 | EP1392642A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 03/03/2004 | EP1392399A1 Use and compositions of antiprogestins for treatment of prostate diseases |
| 03/03/2004 | EP1392366A1 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 03/03/2004 | EP1392361A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| 03/03/2004 | EP1392360A2 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 03/03/2004 | EP1392359A2 Specific binding proteins and uses thereof |
| 03/03/2004 | EP1392351A2 Chemokines as adjuvants of immune response |
| 03/03/2004 | EP1392349A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 03/03/2004 | EP1392345A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| 03/03/2004 | EP1392341A2 Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof |
| 03/03/2004 | EP1392336A1 Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof |
| 03/03/2004 | EP1392334A2 Therapeutic methods using herbal compositions |
| 03/03/2004 | EP1392328A2 Cancer therapy |
| 03/03/2004 | EP1392324A1 Chemoprotection using amifostine and related compounds |
| 03/03/2004 | EP1392317A2 Substituted 1-benzazepines and derivatives thereof |
| 03/03/2004 | EP1392313A1 Combination comprising n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl -4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 03/03/2004 | EP1392311A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 03/03/2004 | EP1392307A1 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| 03/03/2004 | EP1392306A1 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
| 03/03/2004 | EP1392304A1 Use of benzothiophenes to treat and prevent prostate cancer |
| 03/03/2004 | EP1392300A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors |
| 03/03/2004 | EP1392297A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases |
| 03/03/2004 | EP1392296A1 Thiazolidinediones alone or in conbination with other therapeutic agents for inhibiting or reducing tumour growth |
| 03/03/2004 | EP1392293A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| 03/03/2004 | EP1392290A1 Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases |
| 03/03/2004 | EP1392289A2 Caspase inhibitors and uses thereof |
| 03/03/2004 | EP1392286A2 Antineoplastic combinations |
| 03/03/2004 | EP1392279A1 Trimethyl lock based tetrapartate prodrugs |
| 03/03/2004 | EP1392276A1 Potentiation of therapeutic effects of polyunsaturated fatty acids |
| 03/03/2004 | EP1392272A1 Permeation enhancers |
| 03/03/2004 | EP1392268A2 Medicament containing a polyamine as an active substance |
| 03/03/2004 | EP1392266A2 Cancer treatment method and compositions comprising compounds of the ginger family |
| 03/03/2004 | EP1392255A1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
| 03/03/2004 | EP1392241A2 System for osmotic delivery of pharmaceutically active agents |
| 03/03/2004 | EP1392204A2 Bifunctional energy-reversible acyl-compositions |
| 03/03/2004 | EP1392133A2 Functional agent for decomposing nicotine and method of preparing the same |
| 03/03/2004 | EP1196440B1 Therapeutic peptides derived from subsequences of bpi |
| 03/03/2004 | EP1162953B1 Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances |
| 03/03/2004 | EP1124797B1 N-arylsulfonyl amino acid omega amides |
| 03/03/2004 | EP1119252A4 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 03/03/2004 | EP1047437A4 Sea cucumber carotenoid lipid fraction products and methods of use |
| 03/03/2004 | EP1042354B1 Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
| 03/03/2004 | EP1037655B1 use of novel ligands of the neuropeptide receptor hfgan72 and antagonists thereof in therapy |
| 03/03/2004 | EP0948518B1 Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof |
| 03/03/2004 | EP0859628B9 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites |
| 03/03/2004 | EP0831850B1 Use of locally applied dna fragments |
| 03/03/2004 | EP0797447B1 Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| 03/03/2004 | EP0758333B1 Intermediates in pharmaceutical camptothecin preparation |
| 03/03/2004 | EP0719150B1 Cellular vaccine and its use for the treatment of solid tumor malignancies |
| 03/03/2004 | EP0613375B1 Pharmaceutical lysine-containing polypeptide compositions and the use thereof |
| 03/03/2004 | CN1479872A Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing allosteric regulatory site |
| 03/03/2004 | CN1479871A Diagnostic and theraputic methods based on L1 adhesion molecule for ovarian and endometrial tumors |
| 03/03/2004 | CN1479749A Polysaccharide compound having immune stimulating activity |
| 03/03/2004 | CN1479742A Process for preparing substance GM-95 |
| 03/03/2004 | CN1479741A Process for isolation and purification of epothilones |
| 03/03/2004 | CN1479739A Heterocyclic ether substituted imidazoquinolie compounds |